-
Sichuan Kelun-Biotech’s SKB264 Achieves Primary Endpoint in Phase III TNBC Study
•
Sichuan Kelun Pharmaceutical Co., Ltd’s innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), has announced that its Phase III clinical study for SKB264 (MK-2870) has reached its primary endpoint. The study, which is a randomized, controlled, open, multi-center trial, evaluated SKB264 in patients with irresectable local advanced,…
-
WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a memorandum of understanding (MOU) with South Korea-headquartered Boostimmune. This collaboration focuses on research and discovery services related to Boostimmune’s innovative pipelines. Under this agreement, WuXi Bio will serve as Boostimmune’s exclusive research and development service…
-
BioNTech Expands Partnership with Duality Biologics for Global Rights to ADC DB-1305
•
Germany-based BioNTech SE (NASDAQ: BNTC) has entered into a cooperation expansion agreement with its existing partner, Duality Biologics (Suzhou) Co., Ltd. This new deal grants BioNTech global development, manufacturing, and commercialization rights to the antibody drug conjugate (ADC) DB-1305, excluding Greater China, which includes China mainland, Hong Kong, and Macau.…
-
InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs
•
China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum Healthcare. Under the terms of the agreement, GeneQuantum will grant InxMed a non-exclusive license to utilize its independently developed and globally leading core coupling technologies for the development of innovative antibody drug conjugates (ADCs). Access…
-
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for a combination therapy involving its adebrelimab (SHR-1316) with Hansoh Pharmaceutical Group Co., Ltd’s (HKG: 3692) Ameile (almonertinib) or SHR-A2009, with or without chemotherapy, for the treatment…
-
Mabwell Bioscience’s 7MW3711 ADC for B7-H3 Gets Clinical Trial Approval in China
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical trial approval in China for its antibody drug conjugate (ADC), 7MW3711, which targets B7-H3. This ADC is set to be assessed as a potential treatment for advanced solid tumors. B7-H3’s Role in Cancer and 7MW3711’s…
-
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-A1811 and Pyrotinib Combo Study
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase Ib/II clinical study. The study will assess the safety, tolerability, and efficacy of SHR-A1811 in combination with the small-molecule HER2 inhibitor pyrotinib for the treatment…
-
Mabwell Bioscience Receives NMPA Approval to Launch 9MW2921 Clinical Study
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its novel antibody-drug conjugate (ADC), 9MW2921. Next-Generation ADC Based on Mabwell’s IDDC Platform9MW2921 is a next-generation ADC that leverages…
-
GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs
•
China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South Korea-based biotech firm Aimed Bio. The collaboration will see the two companies jointly develop up to five novel antibody drug conjugate (ADC) drugs, with the specific molecular and disease targets undisclosed. This expansion follows last…
-
AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer
•
Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed antibody drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), has been granted a new indication approval in China. This marks the drug’s second approval in the country and is specifically for use as a monotherapy in treating…
-
Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval to introduce Elahere (mirvetuximab soravtansine), an antibody drug conjugate (ADC) targeting folate receptor α (FRα), at Ruijin Hospital’s Hainan branch. The treatment is indicated for FRα positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in…
-
WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the proposed spin-off and separate listing of its subsidiary, WuXi XDC Cayman Inc. (WuXi XDC, HKG: 2268), on the Hong Kong Stock Exchange’s Main Board. WuXi XDC’s Specialized Services in Bioconjugates and ADCsWuXi XDC, a joint…
-
BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development
•
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing agreement with Duality Biotherapeutics, a novel modality drug developer with operations in both the United States and China. This strategic partnership aims to leverage Duality’s expertise in developing innovative therapies. Financial Terms and MilestonesAccording to…
-
Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements
•
China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot firm GL-Biotech in relation to GL-Biotech’s proprietary DisacLink technology. The collaboration aims to achieve technological breakthroughs, jointly develop, improve, and commercialize fixed-point conjugate technology, with both parties engaging in extensive commercial cooperation for the external…
-
Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with Pheon Therapeutics (Pheon), a leading UK-based antibody-drug conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers. According to the agreement, Pheon will develop and commercialize an antibody developed using Biocytogen’s proprietary…
-
Huadong Medicine’s Mirvetuximab Soravtansine Heads for Priority Review by China’s CDE
•
The China’s Center for Drug Evaluation (CDE) website has indicated that Huadong Medicine Co., Ltd (SHE: 000963) is moving forward with a priority review for its mirvetuximab soravtansine, an antibody drug conjugate (ADC), for potential use in folate receptor α (FRα) positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or…
-
Sichuan Biokin Pharmaceutical Gets FDA Approval for BL-B01D1 Clinical Study
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it has received the green light from the US Food and Drug Administration (FDA) to conduct a clinical study for its drug candidate, BL-B01D1. This in-house developed antibody-drug conjugate (ADC) targets EGFR and HER3, key drivers…
-
Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share
•
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), has priced its initial public offering (IPO) filing to the Hong Kong Stock Exchange at a range of HKD 60.6 to 72.8 per share. At an assumed offering price of HKD 60.60…
-
Grand Pharmaceutical Initiates Phase I Study for TLX250-CDx in Renal Mass Imaging
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the Phase I clinical study for its TLX250-CDx (89Zr-DFO-girentuximab), an imaging agent licensed from Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) in a deal valued at up to USD 225 million in 2020. Phase I Study Design…
-
Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics
•
China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine Co., Ltd (SHE: 000963), expanding their strategic partnership initially formed in November 2020. The agreement focuses on the co-development of innovative bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), marking a significant step forward in…
